Swedbank AB Takes Position in Masimo Corporation $MASI

Key Points

• Swedbank AB made a significant investment of $12.65 million in Masimo Corporation by purchasing 75,900 shares during the first quarter, marking a strategic entry into the medical equipment market.
• Other institutional investors, including Twin Tree Management LP and UMB Bank, also increased their stakes in Masimo, reflecting a growing interest in the company's stock.
• Masimo's recent earnings report showed a positive trajectory, with a quarterly revenue increase of 7.7% year-over-year, and the company beat EPS estimates by $0.11.

Swedbank AB purchased a new position in shares of Masimo Corporation (NASDAQ:MASI - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 75,900 shares of the medical equipment provider's stock, valued at approximately $12,645,000. Swedbank AB owned about 0.14% of Masimo at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of Masimo by 58.4% during the first quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock worth $123,000 after purchasing an additional 272 shares during the last quarter. Strs Ohio purchased a new stake in shares of Masimo during the first quarter worth approximately $6,686,000. Intech Investment Management LLC grew its holdings in Masimo by 26.8% during the first quarter. Intech Investment Management LLC now owns 32,494 shares of the medical equipment provider's stock worth $5,414,000 after acquiring an additional 6,872 shares during the period. NBC Securities Inc. acquired a new position in Masimo during the first quarter worth $61,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Masimo by 2.9% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,039 shares of the medical equipment provider's stock worth $673,000 after acquiring an additional 115 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Price Performance

Masimo stock traded down $2.57 during trading hours on Friday, hitting $140.43. The stock had a trading volume of 1,106,202 shares, compared to its average volume of 584,385. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61. The stock has a market capitalization of $7.63 billion, a price-to-earnings ratio of -16.48 and a beta of 1.23. Masimo Corporation has a 1-year low of $113.54 and a 1-year high of $194.88. The stock's fifty day moving average is $150.14 and its two-hundred day moving average is $157.93.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.11. The company had revenue of $370.90 million for the quarter, compared to analyst estimates of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.Masimo's revenue was up 7.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.86 earnings per share. As a group, analysts predict that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director William R. Jellison bought 3,000 shares of the stock in a transaction on Monday, August 11th. The shares were bought at an average price of $145.98 per share, with a total value of $437,940.00. Following the completion of the acquisition, the director owned 4,790 shares of the company's stock, valued at approximately $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 9.70% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on MASI. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Zacks Research raised Masimo from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 3rd. Piper Sandler upped their price objective on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Finally, BTIG Research reaffirmed a "buy" rating and set a $198.00 price objective on shares of Masimo in a report on Thursday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $194.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.